Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.

Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G, Stephens O, Zahalka E, Ringgold K, Helms W, Shord S, Yu J, Zhao H, Davis G, McKee AE, Keegan P, Pazdur R.

Clin Cancer Res. 2016 Nov 1;22(21):5171-5176.

PMID:
27413075
2.

Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions.

Grimaldi C, Finco D, Fort MM, Gliddon D, Harper K, Helms WS, Mitchell JA, O'Lone R, Parish ST, Piche MS, Reed DM, Reichmann G, Ryan PC, Stebbings R, Walker M.

Cytokine. 2016 Sep;85:101-8. doi: 10.1016/j.cyto.2016.06.006.

3.

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.

Nair A, Lemery SJ, Yang J, Marathe A, Zhao L, Zhao H, Jiang X, He K, Ladouceur G, Mitra AK, Zhou L, Fox E, Aungst S, Helms W, Keegan P, Pazdur R.

Clin Cancer Res. 2015 Dec 1;21(23):5205-8. doi: 10.1158/1078-0432.CCR-15-1377.

4.

FDA Approval Summary: Ramucirumab for Gastric Cancer.

Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H, He K, Dougherty M, Novak R, Kennett S, Khasar S, Helms W, Keegan P, Pazdur R.

Clin Cancer Res. 2015 Aug 1;21(15):3372-6. doi: 10.1158/1078-0432.CCR-15-0600.

5.

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, Fox E, Helms W, Leong R, Song P, Pan Y, Liu Q, Zhao P, Zhao H, Lu D, Tang Z, Al Hakim A, Boyd K, Keegan P, Justice R, Pazdur R.

Clin Cancer Res. 2015 Jun 1;21(11):2436-9. doi: 10.1158/1078-0432.CCR-14-3157.

6.

FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.

Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R.

Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Review.

7.

U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.

Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, Helms W, Hanner D, Justice R, Pazdur R.

Clin Cancer Res. 2014 Apr 15;20(8):2029-34. doi: 10.1158/1078-0432.CCR-13-3077.

8.

Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation.

Vatsan RS, Bross PF, Liu K, Theoret M, De Claro AR, Lu J, Helms W, Niland B, Husain SR, Puri RK.

J Immunother Cancer. 2013 May 29;1:5. doi: 10.1186/2051-1426-1-5. Review.

9.

Roundtable on expanding capacity for comparative effectiveness research in the United States: discussion took place on June 3, 2007, at the AcademyHealth Annual Research Meetingin Orlando, FL.

Tunis S, Clancy C, Helms WD, McGinnis JM, Pearson SD.

Health Serv Res. 2009 Apr;44(2 Pt 1):327-42. doi: 10.1111/j.1475-6773.2009.00947.x. No abstract available.

10.

Contrasting roles for all-trans retinoic acid in TGF-beta-mediated induction of Foxp3 and Il10 genes in developing regulatory T cells.

Maynard CL, Hatton RD, Helms WS, Oliver JR, Stephensen CB, Weaver CT.

J Exp Med. 2009 Feb 16;206(2):343-57. doi: 10.1084/jem.20080950.

11.

Modulation of NFAT-dependent gene expression by the RhoA signaling pathway in T cells.

Helms WS, Jeffrey JL, Holmes DA, Townsend MB, Clipstone NA, Su L.

J Leukoc Biol. 2007 Aug;82(2):361-9.

12.

Transforming growth factor-beta induces development of the T(H)17 lineage.

Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT.

Nature. 2006 May 11;441(7090):231-4.

PMID:
16648837
13.
14.

Galpha13 mediates a signal that is essential for proliferation and survival of thymocyte progenitors.

Coffield VM, Helms WS, Jiang Q, Su L.

J Exp Med. 2004 Nov 15;200(10):1315-24.

15.

Real-time quantitative analysis of H2, He, O2, and Ar by quadrupole ion trap mass spectrometry.

Ottens AK, Harrison WW, Griffin TP, Helms WR.

J Am Soc Mass Spectrom. 2002 Sep;13(9):1120-8.

PMID:
12322959
16.

Evaluation of small mass spectrometer systems for permanent gas analysis.

Arkin CR, Griffin TP, Ottens AK, Diaz JA, Follistein DW, Adams FW, Helms WR.

J Am Soc Mass Spectrom. 2002 Aug;13(8):1004-12.

PMID:
12216728
17.

RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification.

Solski PA, Helms W, Keely PJ, Su L, Der CJ.

Cell Growth Differ. 2002 Aug;13(8):363-73.

18.

State coverage expansions: learning from research and practice.

Gauthier AK, Gates VS, Helms WD.

Health Serv Res. 2002 Feb;37(1):33-42. No abstract available.

PMID:
11949924
19.

Identification of chromosomal deficiencies that modify Drosophila mastermind mutant phenotypes.

Yedvobnick B, Helms W, Barrett B.

Genesis. 2001 Aug;30(4):250-8.

PMID:
11536431
20.

1Q[3a]. Allow individuals to buy into the federal health plan?

Moffit RE, Hinchey M, Helms WD.

Hosp Health Netw. 2001 Jun;75(6):32. No abstract available.

PMID:
11432286
Items per page

Supplemental Content

Support Center